Recombinant histone H1 vaccination of monkeys resulted in a slower development of cutaneous lesions compared to controls, suggesting histone H1 can be a candidate for vaccine development against cutaneous leishmaniasis (CL) in humans (7). The gene discussed is H1-0; the disease is cutaneous leishmaniasis.